Literature DB >> 17554518

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Bin Liu1, Fraser Conrad, Audrey Roth, Daryl C Drummond, Jeff P Simko, James D Marks.   

Abstract

We have used a naive human single-chain fragment variable (scFv) library as a source of random shape repertoire to directly probe the altered surface chemistry of tumor cells. We reported previously the identification of more than 90 internalizing phage monoclonal antibodies targeting prostate cancer cells, including those that are hormone refractory. In this report, we describe the conversion of a panel of those scFvs into full-length human immunoglobulins (IgGs) and show that tumor specificity is retained. We have further shown that antibodies isolated from a naive phage display library can nevertheless be of high affinity towards target tumor cells. In addition, full-length IgGs retain the functionality of parental scFvs including the ability to rapidly enter target cells through receptor-mediated endocytosis and thereby to mediate efficient and specific intracellular payload delivery to tumor cells. We have used recombinant IgGs to immunoprecipitate target antigens and analyzed their molecular composition by mass spectrometry. We have identified one target antigen as activated leukocyte cell adhesion molecule (ALCAM)/MEMD/CD166 and have further studied tissue specificity of this internalizing ALCAM epitope by immunohistochemistry. Our study shows that cell type-specific internalizing human antibody can be readily identified from a naive phage antibody display library, characterized with regards to sequence, affinity, tissue specificity, and antigen identity, and modified genetically and chemically to generate various forms of targeted therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554518     DOI: 10.1007/s00109-007-0208-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  51 in total

Review 1.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  CHO expression of a novel human recombinant IgG1 anti-RhD antibody isolated by phage display.

Authors:  S Miescher; M Zahn-Zabal; M De Jesus; R Moudry; I Fisch; M Vogel; M Kobr; M A Imboden; E Kragten; J Bichler; N Mermod; B M Stadler; H Amstutz; F Wurm
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

3.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

4.  Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.

Authors:  Eva Horak; Tara Heitner; Matthew K Robinson; Heidi H Simmons; Jennifer Garrison; Maria Russeva; Polina Furmanova; Jianlong Lou; Yu Zhou; Qing-An Yuan; Louis M Weiner; Gregory P Adams; James D Marks
Journal:  Cancer Biother Radiopharm       Date:  2005-12       Impact factor: 3.099

5.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

6.  Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

Authors:  Laura C Simmons; Dorothea Reilly; Laura Klimowski; T Shantha Raju; Gloria Meng; Paul Sims; Kyu Hong; Robert L Shields; Lisa A Damico; Patricia Rancatore; Daniel G Yansura
Journal:  J Immunol Methods       Date:  2002-05-01       Impact factor: 2.303

Review 7.  Prostate-specific membrane antigen.

Authors:  W R Fair; R S Israeli; W D Heston
Journal:  Prostate       Date:  1997-07-01       Impact factor: 4.104

8.  Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.

Authors:  D C Saffran; A B Raitano; R S Hubert; O N Witte; R E Reiter; A Jakobovits
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

9.  A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy.

Authors:  J E Thompson; T J Vaughan; A J Williams; J Wilton; K S Johnson; L Bacon; J A Green; R Field; S Ruddock; M Martins; A R Pope; P R Tempest; R H Jackson
Journal:  J Immunol Methods       Date:  1999-07-30       Impact factor: 2.303

10.  Expression of a prototypic anti-colorectal cancer polyclonal antibody library in mammalian cells.

Authors:  Liyan Chen; Meredith A Liebman; Sanda Teodorescu-Frumosu; Aletta C Schnitzler; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2003-08-05       Impact factor: 3.685

View more
  19 in total

1.  An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.

Authors:  Katelyn E McCabe; Bin Liu; James D Marks; James S Tomlinson; Hong Wu; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

Review 2.  Selection and characterization of cell binding and internalizing phage antibodies.

Authors:  Yu Zhou; Lequn Zhao; James D Marks
Journal:  Arch Biochem Biophys       Date:  2012-05-22       Impact factor: 4.013

3.  Discovery of internalizing antibodies to tumor antigens from phage libraries.

Authors:  Yu Zhou; James D Marks
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

4.  Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.

Authors:  Xiaodong Zhu; Scott Bidlingmaier; Rintaro Hashizume; C David James; Mitchel S Berger; Bin Liu
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

5.  Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens.

Authors:  Yu Zhou; Hao Zou; Shaoyi Zhang; James D Marks
Journal:  J Mol Biol       Date:  2010-09-17       Impact factor: 5.469

6.  Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.

Authors:  Richard Tavaré; Wei H Wu; Kirstin A Zettlitz; Felix B Salazar; Katelyn E McCabe; James D Marks; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2014-08-04       Impact factor: 1.650

7.  Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Authors:  Fraser Conrad; Xiaodong Zhu; Xin Zhang; Robert J Chalkley; Alma L Burlingame; James D Marks; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2009-02-14       Impact factor: 4.599

8.  Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

Authors:  Feng An; Daryl C Drummond; Shannon Wilson; Dmitri B Kirpotin; Stephen L Nishimura; V Courtney Broaddus; Bin Liu
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

9.  Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Authors:  Yang Su; Yue Liu; Christopher R Behrens; Scott Bidlingmaier; Nam-Kyung Lee; Rahul Aggarwal; Daniel W Sherbenou; Alma L Burlingame; Byron C Hann; Jeffry P Simko; Gayatri Premasekharan; Pamela L Paris; Marc A Shuman; Youngho Seo; Eric J Small; Bin Liu
Journal:  JCI Insight       Date:  2018-09-06

10.  Identification of Novel Macropinocytosing Human Antibodies by Phage Display and High-Content Analysis.

Authors:  K D Ha; S M Bidlingmaier; Y Su; N-K Lee; B Liu
Journal:  Methods Enzymol       Date:  2016-12-01       Impact factor: 1.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.